Stock A009420 HANALL BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
37,300 KRW +2.05% Intraday chart for Hanall Biopharma Co., Ltd. +9.06% -15.80%
05-03 HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease CI
03-06 Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 717.31 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HANALL BIOPHARMA CO., LTD. Stock Hanall Biopharma Co., Ltd.
-15.80% 1.38B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
A+
NOVARTIS AG Stock Novartis AG
+10.02% 209B
B-
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A009420 Stock
  4. Ratings Hanall Biopharma Co., Ltd.